Addex Therapeutics Ltd (SWX:ADXN)
0.0558
+0.0038 (7.31%)
Aug 14, 2025, 4:22 PM CET
Addex Therapeutics Employees
Addex Therapeutics had 2 employees as of December 31, 2024. The number of employees decreased by 21 or -91.30% compared to the previous year.
Employees
2
Change (1Y)
-21
Growth (1Y)
-91.30%
Revenue / Employee
123.09K CHF
Profits / Employee
4.34M CHF
Market Cap
5.49M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2 | -21 | -91.30% |
Dec 31, 2023 | 23 | -1 | -4.17% |
Dec 31, 2022 | 24 | -2 | -7.69% |
Dec 31, 2021 | 26 | -1 | -3.70% |
Dec 31, 2020 | 27 | 8 | 42.11% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Roche Holding AG | 103,249 |
Novartis AG | 75,883 |
Lonza Group AG | 18,944 |
Alcon | 25,599 |
Galderma Group AG | 6,545 |
Sandoz Group AG | 22,049 |
Straumann Holding AG | 11,815 |
Sonova Holding AG | 18,366 |
Addex Therapeutics News
- 6 weeks ago - Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs - GlobeNewsWire
- 6 weeks ago - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders - GlobeNewsWire
- 7 weeks ago - Addex Shareholders Approve All Resolutions at Annual General Meeting - GlobeNewsWire
- 2 months ago - Earnings Scheduled For June 19, 2025 - Benzinga
- 2 months ago - Addex Therapeutics GAAP EPS of -CHF 0.01, income of CHF 0.07M - Seeking Alpha
- 2 months ago - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 - GlobeNewsWire
- 2 months ago - Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models - GlobeNewsWire